Legal Battles and Medical Innovations: A Week in Health News

The health news this week highlights key legal and medical developments. Danco Laboratories is challenging a court's decision that blocks mail-order access to abortion drug mifepristone. Canada approves a generic version of the diabetes drug Ozempic. The FDA approves a new breast cancer drug by Pfizer and Arvinas.

Danco Laboratories has filed an application with the U.S. Supreme Court to halt a decision that restricts mail-order access to the abortion drug mifepristone. The move follows a ruling by a conservative panel, affecting widespread availability, particularly in states banning abortion.

On a different note, Canada's health regulator has approved a generic version of the diabetes medication Ozempic, developed by Apotex, marking it as the second generic alternative authorized in the country.

In other pharmaceutical developments, the U.S. FDA has approved a breast cancer drug from Pfizer and Arvinas, offering new treatment options for advanced estrogen receptor-positive, HER2-negative breast cancer.